Clinical trial evidence for incretin-based diabetes therapies (GLP-1 agonists, DPP-4 inhibitors) demonstrated HbA1c reduction, weight management, and cardiovascular safety — validating the incretin drug class.
Key findingClinical trial evidence for incretin-based diabetes therapies (GLP-1 agonists, DPP-4 inhibitors) demonstrated HbA1c reduction, weight management, and
What the researchers found
Clinical trial evidence for incretin-based diabetes therapies (GLP-1 agonists, DPP-4 inhibitors) demonstrated HbA1c reduction, weight management, and cardiovascular safety — validating the incretin drug class.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Efficacy and safety of incretin based therapies: clinical trial data.
Journal of the American Pharmacists Association : JAPhA, 49 Suppl 1, S30-40
Citation
White, John. (2009). Efficacy and safety of incretin based therapies: clinical trial data.. Journal of the American Pharmacists Association : JAPhA, 49 Suppl 1, S30-40. https://doi.org/10.1331/JAPhA.2009.09079